Phase I Clinical Trials CROs in Asia-Pacific
28 published
28 published CROs match Phase I Clinical Trials in Asia-Pacific.
Locations in this set include India, United States, Australia, United Kingdom, China, and Japan.
Capabilities that show up most often in this set: Biologics (Other), Vaccine, Small Molecule, Cell Therapy, and Gene Therapy.
Matching companies
SMO India Clinical Research Pvt LtdCDSCO-registered CRO with 25+ years of clinical trial experience across Phase I–IV studies in India. Specializes in site management, clinical operations, and regulatory affairs across diverse therapeutic areas.
SPRIM PROClinical trial and strategic consulting CRO offering innovation-enabled trial solutions, digital training, patient engagement programs, and regulatory consulting across multiple therapeutic areas including oncology, CNS, cardiovascular, and rare disease.
Signant HealthClinical trial technology and services provider with 30 years of experience supporting thousands of trials and 25% of novel drug approvals (FDA/EMA, 2021–2024). Offers eClinical solutions, protocol guidance from 50+ in-house scientists and clinicians, and global operational scale.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TFS HealthScienceGlobal mid-size CRO specializing in dermatology, internal medicine, neuroscience, oncology, and ophthalmology with Phase I-IV clinical development, real-world evidence studies, and flexible resourcing solutions across 600+ experts in Europe, North America, and Australia.
TigermedLeading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.
VeranexVeranex is an Innovation CRO uniting design, preclinical, clinical, regulatory, and market-access expertise for medical devices and diagnostics. The company accelerates development from concept through commercialization with integrated cross-disciplinary teams across 15 international hubs.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /services/phase-1-clinical-trials/apac.md